E-mail Print PDF

Prof. Dr. Jan-Christoph Simon


Speaker of Transregio 67

Principal Investigator B3

Prof. Dr. Jan-Christoph Simon,
Professor of Dermatology, Venerology and Allergology

Universität Leipzig
Faculty of Medicine
Clinic for Dermatology, Venerology and Allergology
Philipp-Rosenthal-Straße 23
04103 Leipzig

Phone: +49 (0)341 97-18600
Fax: +49 (0)341 97-18609

E-Mail: jan.simon@medizin.uni-leipzig.de

Curriculum Vitae

1988 – 1991PostDoc "Immunodermatology" at the University of Texas Health and Science Center, Dallas, Texas
with a scholarship of the German Research Foundation (DFG), the Fulbright-Commission & Dermatology Foundation
1994
Habilitation and venia legendi for Dermatology
1994 – 2000 Principal Investigator at the DFG Research Group "Membrane Proteins in Cell Differentiation and Metastasis" at the Karlsruhe Research Centre (Speaker: Prof. Dr. P. Herrlich)
1995 – 1996Principal Investigator at the Collaborative Research Centre SFB 364 "Molecular and Cellular Basics of Tumor Therapy"
1998Heisenberg Fellowship of the DFG at the Karlsruhe Research Centre (Helmholtz Association), Institute of Genetics
1997 – 2003Speaker of the Interdisciplinary Research Group "Pathomechanisms of Allergic Inflammation" at the University Freiburg (funded by the German Ministry of Education and Research)
1999Professor (C3) for Allergology and Immunodermatology at the University of Freiburg
2002 – 2003Principal Investigator at the Collaborative Research Centre SFB 620 "Immunodeficiency in Clinical Medicine and Animal Models"
2003Professor (C4) for Dermatology, Venerology and Allergology at the Faculty of Medicine, Universität Leipzig
since 2005
Principal Investigator at the Collaborative Research Centre SFB 610 "Variation in Protein Conformation : Cell Biological and Pathological Relevance"
since 2006Principal Investigator at the Translational Centre for Regenerative Medicine Leipzig (funded by the German Ministry for Education and Research)
since 2006Member of the German Academy of Sciences Leopoldina
since 2007

Member of the Steering Committee of the Helmholtz International Graduate School for Environmental Research (HIGRADE)

since 2008Member of the Saxonian Academy of Sciences
since 2009Program Committee of the Leipzig Interdisciplinary Research Cluster of Genetic Factors, Clinical Phenotypes and Environment (Excellence Initiative of the Free State of Saxony)

 
Publications (link zu PubMed)

  1. Schneider M, Sülflow K, Loth T, Schulz-Siegmund M, Hacker M, Simon JC, Savkovic V. Mela-nocytes from the outer root sheath of human hair and epidermal melanocytes display improved melanotic features in the niche provided by cGEL, oligomer-cross-linked gelatin-based hydrogel. J Biomed Mater Res. A. 2016, 104:3115-3126.
  2. Savkovic V, Flämig F, Schneider M, Sülflow K, Loth T, Lohrenz A, Hacker MC, Schulz-Siegmund M, Simon JC. Polycaprolactone fiber meshes provide a 3D environment suitable for cultivation and differentiation of melanocytes from the outer root sheath of hair follicle. J Biomed Mater Res. 2016, 104:26-36.
  3. Polte T, Petzold S, Bertrand J, Schütze N, Hinz D, Simon JC, Lehmann I, Echtermeyer F, Pap T, Averbeck M. Critical role for syndecan-4 in dendritic cell migration during development of allergic airway inflammation. Nat Commun. 2015, 6:7554,
  4. Watarai A, Schirmer L, Thönes S, Freudenberg U, Werner C, Simon JC, Anderegg U. TGFß functionalized starPEG-heparin hydrogels modulate human dermal fibroblast growth and differ-entiation. Acta Biomater. 2015, 25:65-75.
  5. Scharnweber D, Hübner L, Rother S, Hempel U, Anderegg U, Samsonov SA, Pisabarro MT, Hofbauer L, Schnabelrauch M, Franz S, Simon JC, Hintze V. Glycosaminoglycan derivatives: promising candidates for the design of functional biomaterials. J Mater Sci Mater Med. 2015, 26(9):232.
  6. Franz S, Rammelt S, Scharnweber D, Simon JC. Immune responses to implants - implications for the design of immunomodulatory biomaterials. Biomaterials. 2011, 32: 6692-709.
  7. Schirmer C, Klein C, von Bergen M, Simon JC*, Saalbach A*. Human fibroblasts support the expansion of IL-17 producing T-cells via up-regulation of IL-23 production by dendritic cells. Blood. 2010, 116:1715-25. (*geteilte Senior-Autorschaft).
  8. Renkl AC, Wussler J, Ahrens Th, Thoma K, Kon S, Uede T, Martin SF, Simon JC, Weiss JM. Osteopontin Functionally Activates Dendritic Cells and Induces their Differentiation Towards a Th-1 Polarizing Phenotype. Blood. 2005, 106:946-55.
  9. Termeer C, Benedix F, Sleeman J, Fieber C, Voith U, Ahrens T, Miyake K, Freudenberg M, Galanos C, Simon JC. Oligosaccharides of Hyaluronan activate Dendritic Cells via the Tolllike Receptor 4. J Exp Med. 2002, 195:99-111.
  10. Weiss JM, Renkl AC, Maier CS, Kimmig M, Liaw L, Ahrens T, Kon S, Maeda M, Hotta H, Uede T, Simon JC. Osteopontin is involved in the the Initiation of Cutaneous Contact Hypersensitivity by Inducing Langerhans and Dendritic Cell Migration to Lymph Nodes. J Exp Med. 2001, 194:1219-29.
Patente (angemeldete und erteilte)
  1. Method for deriving melanocytes from the hair follicle outer root sheath and preparation for grafting. European Patent Pending 11 18 6944.2 (Publication number: WO2013060899 A3, Submitted 2011, published 2013, national entry phase 2014 (EU, US, Korea, Japan, Australia, NZ, Indonesia); US 14/354,545 (S3357 US BLN); CA 2853580; JP 2014537655; AU 2012328353; KR 20147014317)
  2. Method for deriving melanocytes from the hair follicle outer root sheath and preparation for grafting. European Patent Pending 11 18 6944.2 (Publication number: WO2013060899 A3, 2016)
  3. Hyperforin as Cytostatic agent and Hyperforin ointment or cream as application form, Universi-tätsklinikum Freiburg, ZEE 199804428 (US-Patent 7,179,495, 2007)
  4. Verfahren und Testsystem zur in vitro Analyse von potentiell anti-entzündlichen oder anti-metastatischen Substanzen (Dt. Patentamt AZ: P 10 2006 012 918.0, 2006)
  5. Hyperforin Salbe oder Creme, deren Herstellung und Anwendung (Dt. Patentamt AZ 198 54 446.4, 1999)
  6. Hyperforin als Zytostatikum sowie Hyperforin-Salbe oder -Creme als Applikationsform (Dt. Pa-tentamt AZ 199 13 333.6/ PCT/ EP99/ 09067, 1998)
  7. Niedermolekulare Fragmente der Hyaluronsäure zur Herstellung von Impfstoffen (Dt. Pa-tentamt AZ 198 53 066.8IPCT/ EP99/ 06280, 1998)
  8. Verfahren zur Herstellung von dendritischen Zellen mit niedermolekularen Fragmenten der Hya-luronsäure (Dt. Patentamt AZ 19802540.8 und 19839113.7, 1997)
  9. Verwendung von anti-CD44-Antikörpern enthaltenden Präparationen zur Behandlung bes-timmter Tumore und zur Unterdrückung von Immunreaktionen (Dt. Patentamt AZ 19708713.2, 1997)